The Ledger

COO

Cooper Companies IncHealth Careinsider_universe

Last close $62.65Nov 12, 2026

Day +0.74%

Currently held

Agent 21 — Insider Clusterlong
91 sh @ $54.61 · stop $50.24
+$732.55 unrealized
Agent 8 — Dip Buyer (Peer-Aware)long
31 sh @ $56.91 · stop $51.58
+$178.13 unrealized

Everything we've seen

·Nov 15, 11:30 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 11:15 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 11:00 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 10:45 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 10:30 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 10:15 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 10:00 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 9:45 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 9:30 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 9:15 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 9:00 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 8:45 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 8:30 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 8:15 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 8:01 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 7:45 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 7:30 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 7:15 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 7:00 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 6:45 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 6:30 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 6:15 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 6:01 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 5:45 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
·Nov 15, 5:30 AMstreamnews
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
❖Nov 13, 7:12 AMnewsvia finnhub
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.
❖Nov 12, 8:35 AMnewsvia finnhub
Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of +25.58% and +2.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
❖Nov 11, 6:50 AMnewsvia finnhub
Cooper Companies (NASDAQ:COO): A Decent Value Stock With Margin of Safety
Cooper Companies fits the Decent Value screen with cheap valuation, solid profitability and health, though slower growth and weak liquidity need monitoring.
❖Nov 10, 1:58 PMnewsvia finnhub
Top 5 Activist Target Stocks for Spin-offs or Breakups
We just published the Top 10 Activist Target Stocks for Spin-offs or Breakups. You can find the top 5 stocks below. Activist investors have increasingly targeted companies with complex corporate structures, underperforming business divisions, or undervalued assets. The argument is that breaking up businesses or spinning off non-core operations could help unlock much-needed shareholder value. […]
❖Nov 10, 10:40 AMnewsvia finnhub
What Changed For Warby Parker Stock, And What Did Not?
For questions about this article or underlying research, email help@trefis.com.
❖Nov 10, 8:11 AMnewsvia finnhub
Why Is Warby Parker Stock Going Up?
For questions about this article or underlying research, email help@trefis.com.
❖Nov 9, 5:35 PMnewsvia finnhub
Lifevantage (LFVN) Surpasses Q1 Earnings Estimates
Lifevantage (LFVN) delivered earnings and revenue surprises of +66.67% and -3.84%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
?Nov 6, 10:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COO is down 2.24% intraday with no headline catalyst visible, suggesting this is flow/technical driven selling rather than a news event that might quickly exhaust. The move is meaningful but not extreme, and with 340 minutes remaining (essentially most of the trading day still ahead), there is ample time for continuation if sellers remain in control. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to COO (Cooper Companies, a medical devices/contact lens company), so no macro tailwind or headwind amplifies the move. Absence of news is not a fade signal per se. The setup is borderline — no strong sector catalyst, no confirming news, but a real intraday move with time remaining. No clear reversal pattern is evident from the data provided. Assigning a modest continuation probability slightly above 0.5 reflecting ordinary downside momentum with no strong reason to expect a fade, but also no high-conviction continuation signal.
!Nov 6, 10:06 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
COO is down 2.24% intraday with no headline catalyst visible, suggesting this is flow/technical driven selling rather than a news event that might quickly exhaust. The move is meaningful but not extreme, and with 340 minutes remaining (essentially most of the trading day still ahead), there is ample time for continuation if sellers remain in control. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to COO (Cooper Companies, a medical devices/contact lens company), so no macro tailwind or headwind amplifies the move. Absence of news is not a fade signal per se. The setup is borderline — no strong sector catalyst, no confirming news, but a real intraday move with time remaining. No clear reversal pattern is evident from the data provided. Assigning a modest continuation probability slightly above 0.5 reflecting ordinary downside momentum with no strong reason to expect a fade, but also no high-conviction continuation signal.
❖Nov 6, 4:35 AMnewsvia finnhub
Diamond Hill Large Cap Fund Q3 2026 Portfolio Update
Diamond Hill Large Cap Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Read more here.
❖Nov 5, 5:23 PMnewsvia finnhub
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2026
SAN RAMON, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report fourth quarter and full year 2026 financial results on Thursday, December 3, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1193290. A simultaneous audio webcast
?Nov 5, 2:56 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COO is down 2.13% with 50 minutes remaining, which is a meaningful move but sits at the lower boundary of the 2-5% 'conviction' range. No headlines are available to explain the move or suggest a catalyst that would sustain it. The macro context (DFF elevated 2.1σ above trend) is modestly negative for growth/non-financial equities but COO (Cooper Companies, medical devices/contact lenses) is not a primary rate-sensitive sector — the macro tailwind for continuation is weak. With only 50 minutes to close, there is limited time for further downside to develop, and late-session profit-taking by intraday shorts is a real risk. The absence of news cuts both ways, but the combination of modest move magnitude, no clear catalyst, limited time remaining, and a macro context that is only tangentially relevant pushes the probability just below the 0.5 threshold. I do not see a strong reason to expect a reversal, but I also cannot identify clear continuation pressure, making this a borderline fade rather than a continuation setup.
!Nov 5, 2:56 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
COO is down 2.13% with 50 minutes remaining, which is a meaningful move but sits at the lower boundary of the 2-5% 'conviction' range. No headlines are available to explain the move or suggest a catalyst that would sustain it. The macro context (DFF elevated 2.1σ above trend) is modestly negative for growth/non-financial equities but COO (Cooper Companies, medical devices/contact lenses) is not a primary rate-sensitive sector — the macro tailwind for continuation is weak. With only 50 minutes to close, there is limited time for further downside to develop, and late-session profit-taking by intraday shorts is a real risk. The absence of news cuts both ways, but the combination of modest move magnitude, no clear catalyst, limited time remaining, and a macro context that is only tangentially relevant pushes the probability just below the 0.5 threshold. I do not see a strong reason to expect a reversal, but I also cannot identify clear continuation pressure, making this a borderline fade rather than a continuation setup.
?Nov 5, 12:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COO is down 2.02% today with no directly attributable headline — the Cardinal Health earnings beat is sector-adjacent (healthcare) but not a direct COO catalyst, and could even reflect rotation out of other healthcare names. The macro context shows elevated fed funds rate (3.88, 2.1σ above trend), which is a mild headwind for growth-oriented or rate-sensitive names but not a sharp sector-specific pressure on COO (a medical device/contact lens company). With 215 minutes remaining there is ample time for continuation, and a ~2% move does represent meaningful selling flow. However, there is no clear catalyst to anchor the move, no reversal pattern evident, and the macro context is not acutely bearish for this sector. The setup is borderline — momentum exists and time is sufficient, but conviction is low without a clear driver. Assigning 0.50 as a neutral-momentum read that just clears the action threshold given the system's bounded risk profile.
!Nov 5, 12:10 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
COO is down 2.02% today with no directly attributable headline — the Cardinal Health earnings beat is sector-adjacent (healthcare) but not a direct COO catalyst, and could even reflect rotation out of other healthcare names. The macro context shows elevated fed funds rate (3.88, 2.1σ above trend), which is a mild headwind for growth-oriented or rate-sensitive names but not a sharp sector-specific pressure on COO (a medical device/contact lens company). With 215 minutes remaining there is ample time for continuation, and a ~2% move does represent meaningful selling flow. However, there is no clear catalyst to anchor the move, no reversal pattern evident, and the macro context is not acutely bearish for this sector. The setup is borderline — momentum exists and time is sufficient, but conviction is low without a clear driver. Assigning 0.50 as a neutral-momentum read that just clears the action threshold given the system's bounded risk profile.
❖Nov 5, 10:12 AMnewsvia finnhub
Stocks To Consider Ahead Of The Upcoming October 2026 CPI Report
Federal Reserve held rates at 3.75%-4.00% amid elevated inflation and resilient domestic spending, with a 25 bps hike next month. Read full analysis here.
❖Nov 5, 7:15 AMnewsvia finnhub
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
Cardinal (CAH) delivered earnings and revenue surprises of +11.64% and +0.83%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
?Nov 4, 11:31 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COO is up 5.56% with no attributable headline, suggesting this is likely flow-driven — institutional repositioning or a catalyst not yet publicly surfaced. A move of this magnitude represents real conviction. However, several factors temper enthusiasm: (1) No news to anchor a narrative or attract additional buyers into the close. (2) The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly risk-off for equities broadly, though COO (Cooper Companies, medical devices) is not a primary rate-sensitive sector. (3) With 255 minutes remaining the session is still early-to-mid, leaving meaningful time for the move to either extend or fade. (4) A 5.56% gap-style move without a catalyst raises some fade risk — profit-takers and mean-reversion algos will be active. On balance, the momentum evidence alone is sufficient to tip slightly above 0.5. The bounded risk framework (1.5% stop, 3% target, forced flatten at 3:45) makes a modest continuation bet reasonable here, but conviction is low.
!Nov 4, 11:31 AMsignalseverity 0.06
Agent 7 — Day Trader — day_trade_skipped
COO is up 5.56% with no attributable headline, suggesting this is likely flow-driven — institutional repositioning or a catalyst not yet publicly surfaced. A move of this magnitude represents real conviction. However, several factors temper enthusiasm: (1) No news to anchor a narrative or attract additional buyers into the close. (2) The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly risk-off for equities broadly, though COO (Cooper Companies, medical devices) is not a primary rate-sensitive sector. (3) With 255 minutes remaining the session is still early-to-mid, leaving meaningful time for the move to either extend or fade. (4) A 5.56% gap-style move without a catalyst raises some fade risk — profit-takers and mean-reversion algos will be active. On balance, the momentum evidence alone is sufficient to tip slightly above 0.5. The bounded risk framework (1.5% stop, 3% target, forced flatten at 3:45) makes a modest continuation bet reasonable here, but conviction is low.
?Nov 4, 10:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COO is up 4.26% intraday with no attributable headline, suggesting institutional flow or a catalyst not yet reflected in public news. The move is meaningful and represents real conviction. However, several factors temper enthusiasm: (1) At 340 minutes remaining (early in the session), there is ample time for the move to either continue or revert — not a time-pressure argument either way. (2) The macro context shows DFF at 2.1σ above 24-month trend, indicating elevated short-term rates, which is a mild headwind for non-bank equities generally and does not provide a tailwind for COO (medical devices/contact lenses sector). (3) No news to anchor the move raises the possibility of a gap-fill fade if the catalyst is thin. (4) A 4.26% move without news in a mid-cap stock like COO can attract mean-reversion sellers into the afternoon. Balancing the momentum signal (which by itself argues for continuation) against the lack of a news catalyst, slightly elevated rate environment, and fade risk from profit-taking, I assign a modest continuation probability just above the threshold. The bounded risk profile (1.5% stop, 3% target) makes a slight lean toward continuation the correct posture here.
!Nov 4, 10:06 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
COO is up 4.26% intraday with no attributable headline, suggesting institutional flow or a catalyst not yet reflected in public news. The move is meaningful and represents real conviction. However, several factors temper enthusiasm: (1) At 340 minutes remaining (early in the session), there is ample time for the move to either continue or revert — not a time-pressure argument either way. (2) The macro context shows DFF at 2.1σ above 24-month trend, indicating elevated short-term rates, which is a mild headwind for non-bank equities generally and does not provide a tailwind for COO (medical devices/contact lenses sector). (3) No news to anchor the move raises the possibility of a gap-fill fade if the catalyst is thin. (4) A 4.26% move without news in a mid-cap stock like COO can attract mean-reversion sellers into the afternoon. Balancing the momentum signal (which by itself argues for continuation) against the lack of a news catalyst, slightly elevated rate environment, and fade risk from profit-taking, I assign a modest continuation probability just above the threshold. The bounded risk profile (1.5% stop, 3% target) makes a slight lean toward continuation the correct posture here.
?Nov 2, 10:11 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COO is up 1.68% today with no attributable news catalyst. The move is modest but real, suggesting some directional flow. However, several factors temper conviction: (1) The macro backdrop features elevated mortgage rates (7.24%, +2.3σ above trend), which creates mild headwinds for financials and rate-sensitive sectors — COO (Cooper Companies, medical devices/contact lenses) is not directly in the blast radius of mortgage rates, so this is largely neutral. (2) With 335 minutes remaining (over 5.5 hours), there is ample time for the move to either extend or fade — time is not a constraint here. (3) No news catalyst means we cannot identify a fundamental driver, but per guidelines, absence of news is not a disqualifier. (4) A 1.68% move is below the 2-5% threshold that would constitute strong conviction flow, keeping this in the ordinary momentum bucket. (5) No reversal pattern is indicated — price is simply up on the day. On balance, this is a mild upward momentum setup with no strong reason to expect a fade. Assigning a modest continuation probability just above the action threshold.
!Nov 2, 10:11 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
COO is up 1.68% today with no attributable news catalyst. The move is modest but real, suggesting some directional flow. However, several factors temper conviction: (1) The macro backdrop features elevated mortgage rates (7.24%, +2.3σ above trend), which creates mild headwinds for financials and rate-sensitive sectors — COO (Cooper Companies, medical devices/contact lenses) is not directly in the blast radius of mortgage rates, so this is largely neutral. (2) With 335 minutes remaining (over 5.5 hours), there is ample time for the move to either extend or fade — time is not a constraint here. (3) No news catalyst means we cannot identify a fundamental driver, but per guidelines, absence of news is not a disqualifier. (4) A 1.68% move is below the 2-5% threshold that would constitute strong conviction flow, keeping this in the ordinary momentum bucket. (5) No reversal pattern is indicated — price is simply up on the day. On balance, this is a mild upward momentum setup with no strong reason to expect a fade. Assigning a modest continuation probability just above the action threshold.
❖Oct 31, 12:51 AMnewsvia finnhub
3 Reasons COO is risky and 1 stock to buy instead
Since April 2026, CooperCompanies has been in a holding pattern, posting a small loss of 4% while floating around $60.41. The stock also fell short of the S&P 500’s 7.5% gain during that period.
❖Oct 30, 2:14 AMnewsvia finnhub
Cooper Companies (COO) Faces A CEO Exit, Is The Stock Still Cheap?
Cooper Companies (COO) is undergoing a leadership change after Albert White stepped down as president and CEO. Board member Walter Rosebrough has stepped in as executive chair and is overseeing day-to-day operations. Recent trading tells you investors are still cautious on Cooper Companies. The share price is up 6.74% over the past month to US$60.34 but down 16.57% over 90 days, while the 1 year total shareholder return has declined 13.69%. This suggests momentum has been fading despite...
❖Oct 29, 11:58 AMnewsvia finnhub
Cooper Companies CEO steps down after activist investor pressure
Weeks after an investor called for leadership changes, Cooper has parted ways with its CEO and proposed a new-look board of directors.
❖Oct 29, 5:59 AMnewsvia finnhub
Cooper Companies' Quarterly Earnings Preview: What You Need to Know
Cooper Companies is expected to announce its fourth-quarter earnings soon, and analysts expect a single-digit EPS fall.
❖Oct 29, 5:39 AMnewsvia finnhub
3 unpopular stocks we keep off our radar
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
❖Oct 28, 4:02 PMnewsvia finnhub
Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance
Key TakeawaysBausch + Lomb shares jumped 16% after a third-quarter profit beat and raised full-year guidance. Profit is the story: adjusted EBITDA rose 34% on 7% revenue growth.
❖Oct 27, 4:28 PMnewsvia finnhub
CooperCompanies Announces Leadership Transition and Board Refreshment
Independent Director and Seasoned Healthcare Executive Walt Rosebrough Elected Executive Chair; Search for CEO UnderwayProvides Update on Board Refreshment, Including Planned Addition of Medical Device and Vision Veteran Shlomi NachmanReaffirms Full-Year Fiscal 2026 GuidanceSAN RAMON, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) (the “Company”), a leading medical device company, today announced leadership changes and planned Board refreshment aimed at strengthening ope
❖Oct 27, 1:34 PMnewsvia finnhub
3 mid-cap stocks that concern us
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
❖Oct 27, 12:30 PMnewsvia finnhub
CooperCompanies Appoints Walter M Rosebrough, Jr. As Board Chair, Succeeding Albert White III, Who Is Stepping Down As CEO, Chair; Co. Reiterates FY26 Outlook
CooperCompanies (Nasdaq: COO) (the "Company"), a leading medical device company, today announced leadership changes and planned Board refreshment aimed at strengthening operational execution, improving business
❖Oct 23, 2:14 PMnewsvia finnhub
Cooper Companies (COO) Stock Looks Undervalued On Current Earnings
Cooper Companies has climbed in recent weeks even though its longer term returns have been weak, which puts a spotlight on whether the current share price lines up with what its earnings justify. With fresh headlines around softer results and legal investigations still in view in late 2026, the question for you is how much profit power is already baked into the stock. Over the past 5 years the share price has fallen 40.8%, so any assessment of Cooper Companies today needs to weigh a...
✓Oct 22, 11:05 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — pyramid
Pyramid add-on fired at +10.03% unrealized. Added 10 sh @ $60.66 ($606.60). Position now 31 sh @ weighted avg $56.91.
?Oct 22, 10:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COO is up 1.70% today, a modest but real move suggesting some directional conviction. There are no news catalysts to explain the move, which is common — flow-driven moves can persist. However, several factors temper enthusiasm: (1) The move is only 1.70%, below the 2-5% threshold that signals high-conviction institutional flow. (2) Macro context shows 2-year yields elevated at 2.1σ above trend, which creates a headwind for rate-sensitive or growth-oriented names and broadly compresses risk appetite. COO (Cooper Companies) is a medical device/consumer health name — not a direct rate beneficiary, but elevated rates can weigh on valuation multiples. (3) With 335 minutes remaining (~5.5 hours), there is ample time for continuation, but also ample time for fade. (4) No supportive news or sector catalyst to anchor the move. Net assessment: weak positive momentum with no clear reason to fade it, but also no strong continuation signal. Defaulting to slight continuation bias per the framework's asymmetric cost structure.
!Oct 22, 10:10 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
COO is up 1.70% today, a modest but real move suggesting some directional conviction. There are no news catalysts to explain the move, which is common — flow-driven moves can persist. However, several factors temper enthusiasm: (1) The move is only 1.70%, below the 2-5% threshold that signals high-conviction institutional flow. (2) Macro context shows 2-year yields elevated at 2.1σ above trend, which creates a headwind for rate-sensitive or growth-oriented names and broadly compresses risk appetite. COO (Cooper Companies) is a medical device/consumer health name — not a direct rate beneficiary, but elevated rates can weigh on valuation multiples. (3) With 335 minutes remaining (~5.5 hours), there is ample time for continuation, but also ample time for fade. (4) No supportive news or sector catalyst to anchor the move. Net assessment: weak positive momentum with no clear reason to fade it, but also no strong continuation signal. Defaulting to slight continuation bias per the framework's asymmetric cost structure.
?Oct 21, 7:00 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 21, 7:00 AMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COO (Cooper Companies) is down 18.8% from its 30-day high, but there are no news headlines or SEC filing metrics in the evidence window to explain company-specific deterioration — the 10-Q and 8-K filings lack reported metrics, making it difficult to confirm or deny fundamental stress. Cooper Companies operates primarily in medical devices (contact lenses and fertility), which is not directly sensitive to mortgage rates, so the elevated MORTGAGE30US macro reading (7.4%, 3.3σ above trend) is unlikely to be a primary driver of this drop. The absence of negative catalysts suggests this may be a technically-driven or broader market-related pullback rather than a fundamental breakdown, though the lack of data limits conviction.
!Oct 20, 6:01 PMsignalseverity 0.13
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COO (Cooper Companies) is down 18.8% from its 30-day high, but there are no news headlines or SEC filing metrics in the evidence window to explain company-specific deterioration — the 10-Q and 8-K filings lack reported metrics, making it difficult to confirm or deny fundamental stress. Cooper Companies operates primarily in medical devices (contact lenses and fertility), which is not directly sensitive to mortgage rates, so the elevated MORTGAGE30US macro reading (7.4%, 3.3σ above trend) is unlikely to be a primary driver of this drop. The absence of negative catalysts suggests this may be a technically-driven or broader market-related pullback rather than a fundamental breakdown, though the lack of data limits conviction.
?Oct 20, 4:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 4:20 PMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 3:20 PMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 2:21 PMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 1:20 PMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 12:20 PMsignalseverity 0.14
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 11:20 AMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 10:20 AMsignalseverity 0.14
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 20, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 20, 7:01 AMsignalseverity 0.16
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
❖Oct 20, 6:53 AMnewsvia finnhub
3 S&P 500 Stocks We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
?Oct 19, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COO (Cooper Companies) is down 18.8% from its 30-day high, but there are no news headlines or SEC filing metrics in the evidence window to explain company-specific deterioration — the 10-Q and 8-K filings lack reported metrics, making it difficult to confirm or deny fundamental stress. Cooper Companies operates primarily in medical devices (contact lenses and fertility), which is not directly sensitive to mortgage rates, so the elevated MORTGAGE30US macro reading (7.4%, 3.3σ above trend) is unlikely to be a primary driver of this drop. The absence of negative catalysts suggests this may be a technically-driven or broader market-related pullback rather than a fundamental breakdown, though the lack of data limits conviction.
!Oct 19, 6:01 PMsignalseverity 0.16
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COO (Cooper Companies) is down 18.8% from its 30-day high, but there are no news headlines or SEC filing metrics in the evidence window to explain company-specific deterioration — the 10-Q and 8-K filings lack reported metrics, making it difficult to confirm or deny fundamental stress. Cooper Companies operates primarily in medical devices (contact lenses and fertility), which is not directly sensitive to mortgage rates, so the elevated MORTGAGE30US macro reading (7.4%, 3.3σ above trend) is unlikely to be a primary driver of this drop. The absence of negative catalysts suggests this may be a technically-driven or broader market-related pullback rather than a fundamental breakdown, though the lack of data limits conviction.
?Oct 19, 4:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 4:20 PMsignalseverity 0.16
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 19, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 3:20 PMsignalseverity 0.16
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 19, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 2:20 PMsignalseverity 0.16
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 19, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 1:20 PMsignalseverity 0.16
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 19, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 12:20 PMsignalseverity 0.17
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 19, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 11:20 AMsignalseverity 0.16
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 19, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 10:20 AMsignalseverity 0.17
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 19, 7:00 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 19, 7:00 AMsignalseverity 0.18
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COO (Cooper Companies) is down 18.8% from its 30-day high, but there are no news headlines or SEC filing metrics in the evidence window to explain company-specific deterioration — the 10-Q and 8-K filings lack reported metrics, making it difficult to confirm or deny fundamental stress. Cooper Companies operates primarily in medical devices (contact lenses and fertility), which is not directly sensitive to mortgage rates, so the elevated MORTGAGE30US macro reading (7.4%, 3.3σ above trend) is unlikely to be a primary driver of this drop. The absence of negative catalysts suggests this may be a technically-driven or broader market-related pullback rather than a fundamental breakdown, though the lack of data limits conviction.
!Oct 16, 6:02 PMsignalseverity 0.18
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COO (Cooper Companies) is down 18.8% from its 30-day high, but there are no news headlines or SEC filing metrics in the evidence window to explain company-specific deterioration — the 10-Q and 8-K filings lack reported metrics, making it difficult to confirm or deny fundamental stress. Cooper Companies operates primarily in medical devices (contact lenses and fertility), which is not directly sensitive to mortgage rates, so the elevated MORTGAGE30US macro reading (7.4%, 3.3σ above trend) is unlikely to be a primary driver of this drop. The absence of negative catalysts suggests this may be a technically-driven or broader market-related pullback rather than a fundamental breakdown, though the lack of data limits conviction.
?Oct 16, 4:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 16, 4:20 PMsignalseverity 0.18
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 3:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 16, 3:21 PMsignalseverity 0.18
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
!Oct 16, 2:21 PMsignalseverity 0.18
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 16, 7:00 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COO (Cooper Companies) is down 18.8% from its 30-day high, but there are no news headlines or SEC filing metrics in the evidence window to explain company-specific deterioration — the 10-Q and 8-K filings lack reported metrics, making it difficult to confirm or deny fundamental stress. Cooper Companies operates primarily in medical devices (contact lenses and fertility), which is not directly sensitive to mortgage rates, so the elevated MORTGAGE30US macro reading (7.4%, 3.3σ above trend) is unlikely to be a primary driver of this drop. The absence of negative catalysts suggests this may be a technically-driven or broader market-related pullback rather than a fundamental breakdown, though the lack of data limits conviction.
?Oct 15, 4:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COO is down ~19.7% from its 30-day high with no visible fundamental cause in the SEC filings (empty metrics in both the 8-K and 10-Q), suggesting the drop may be noise or sector rotation rather than deterioration. Health Care ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY meaningfully on both a 5-day and 30-day basis, which means the sell-off appears idiosyncratic to COO rather than sector-wide — a mild negative signal. Earnings are 48 days away (clean runway), VIX is benign at the 14th percentile, and options flow is neutral (P/C 0.90, both call and put volumes below average z-scores).
?Oct 15, 7:00 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
The drop is clearly idiosyncratic and fundamental: COO missed Q3 revenue estimates due to destocking, failed to sell CooperSurgical at an attractive valuation (BofA), received multiple analyst downgrades with commentary citing "limited near-term appeal," and is heading toward a 52-week low. Options flow is decisively bearish with put volume at a z-score of 72.82 versus call z-score of 4.30, a P/C ratio of 1.59 — signaling informed institutional hedging/selling, not dip-buying. There are no insider purchases to suggest internal conviction in a recovery.
?Oct 14, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COO is down 31% from its 30-day high, which is a significant drawdown, but the news headlines don't indicate catastrophic deterioration — the weakness cited is in CooperVision, a known cyclical segment, while the company is actively pivoting toward fertility growth as an offset. However, the macro context is a headwind: the 5-year forward inflation rate is running 1.8σ above its 24-month trend, which pressures rate-sensitive and leveraged businesses like COO. The 10-Q and 8-K filings lack disclosed metrics, preventing confirmation of earnings quality, and the muted news sentiment suggests the market may be pricing in persistent segment weakness rather than a transitory dip.
?Oct 14, 4:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
The drop is clearly idiosyncratic and fundamental: COO missed Q3 revenue estimates due to destocking, failed to sell CooperSurgical at an attractive valuation (BofA), received multiple analyst downgrades with commentary citing "limited near-term appeal," and is heading toward a 52-week low. Options flow is decisively bearish with put volume at a z-score of 72.82 versus call z-score of 4.30, a P/C ratio of 1.59 — signaling informed institutional hedging/selling, not dip-buying. There are no insider purchases to suggest internal conviction in a recovery.
?Oct 14, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
The drop is clearly idiosyncratic and fundamental: COO missed Q3 revenue estimates due to destocking, failed to sell CooperSurgical at an attractive valuation (BofA), received multiple analyst downgrades with commentary citing "limited near-term appeal," and is heading toward a 52-week low. Options flow is decisively bearish with put volume at a z-score of 72.82 versus call z-score of 4.30, a P/C ratio of 1.59 — signaling informed institutional hedging/selling, not dip-buying. There are no insider purchases to suggest internal conviction in a recovery.
?Oct 14, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
The drop is clearly idiosyncratic and fundamental: COO missed Q3 revenue estimates due to destocking, failed to sell CooperSurgical at an attractive valuation (BofA), received multiple analyst downgrades with commentary citing "limited near-term appeal," and is heading toward a 52-week low. Options flow is decisively bearish with put volume at a z-score of 72.82 versus call z-score of 4.30, a P/C ratio of 1.59 — signaling informed institutional hedging/selling, not dip-buying. There are no insider purchases to suggest internal conviction in a recovery.
?Oct 14, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
The drop is clearly idiosyncratic and fundamental: COO missed Q3 revenue estimates due to destocking, failed to sell CooperSurgical at an attractive valuation (BofA), received multiple analyst downgrades with commentary citing "limited near-term appeal," and is heading toward a 52-week low. Options flow is decisively bearish with put volume at a z-score of 72.82 versus call z-score of 4.30, a P/C ratio of 1.59 — signaling informed institutional hedging/selling, not dip-buying. There are no insider purchases to suggest internal conviction in a recovery.
❖Oct 14, 11:32 AMnewsvia finnhub
Medical Devices & Supplies - Diversified Stocks Q2 Highlights: CooperCompanies (NASDAQ:COO)
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q2, starting with CooperCompanies (NASDAQ:COO).
❖Oct 9, 10:30 AMnewsvia finnhub
Why Is The Cooper Companies (COO) Up 0.2% Since Last Earnings Report?
The Cooper Companies (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
❖Oct 7, 11:58 AMnewsvia finnhub
Cooper Companies Director Kurzius Buys 10,000 Shares for $539,100. What Does This Insider See in Shares?
Kurzius doubled his direct stake in the medical device company despite a 19% one-year stock decline, signaling confidence in COO's turnaround prospects.
❖Oct 7, 10:58 AMnewsvia finnhub
Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?
Keel purchased 4,701 shares at $53.18 each following a 21% year-long decline, signaling confidence in the medical device company's valuation.
❖Oct 7, 10:00 AMnewsvia finnhub
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls
❖Oct 7, 5:16 AMnewsvia finnhub
Barclays Initiates Coverage On Cooper Companies with Equal-Weight Rating, Announces Price Target of $60
Barclays analyst Christopher Pasquale initiates coverage on Cooper Companies (NASDAQ:COO) with a Equal-Weight rating and announces Price Target of $60.
❖Oct 6, 7:10 PMnewsvia finnhub
Cooper Companies Director Rosebrough Buys 10,000 Shares for $542,000. What Does His Move Say About This Eye Care Stock?
Insider purchased shares through his revocable trust following a 19% stock decline over the past year, doubling his indirect holdings to 20,000 shares.
❖Oct 5, 12:30 PMnewsvia finnhub
CDT Insider Sentiment September 2026 - A Quiet Market Drawdown And Two Opposing Thoughts
Underneath the surface of this monthâs modest -.35% index level decline was a somewhat nasty market drawdown. Insider Sentiment climbed sharply into the September drawdown. Read more here.
❖Oct 2, 1:31 PMnewsvia finnhub
Cooper Companies Director Kurzius Buys $549,300 in Shares. Is the Eye Care Stock About to Rally?
Insider doubled down after stock fell 16% over the past year, signaling confidence in the contact lens and surgical care provider's recovery prospects.
❖Oct 1, 8:05 AMnewsvia finnhub
New CooperVision® Consumer Insights Report Reveals Multifocal Contact Lenses Are Viewed as a Leading Anti-Aging Solution
New research from CooperVision reveals that vision remains an overlooked, yet high potential part of the healthy aging conversation as consumers increasingly invest in products and services that help them look and feel younger. The Unmet Opportunities: Multifocal Contact Lenses and the Anti-Aging Movement (U.S.) report highlights evolving attitudes towards aging and receptiveness to multifocal contact lenses, revealing largely untapped opportunities for eye care professionals (ECPs) to introduce
❖Sep 29, 9:00 AMnewsvia finnhub
Seneca Polytechnic and CooperVision Canada open Contact Lens Centre of Excellence to help advance the future of vision care
New facility expands hands-on learning opportunities and strengthens connections between education, industry and patient care CooperVision Contact Lens Centre of Excellence The new CooperVision Contact Lens Centre of Excellence at Newnham Campus provides students with experiences that reflect today’s evolving eye care environment. TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- As the demand for vision care continues to grow, preparing the next generation of eye care professionals has never been mor
❖Sep 27, 9:49 PMnewsvia finnhub
Is Jana Partners Right that Cooper (COO) Needs a Different Kind of Leadership?
Activist campaigns tend to surface when a stock’s performance no longer matches its story, and The Cooper Companies, Inc. (NASDAQ:COO) is a case in point. In mid-September 2026, Jana Partners, which built its stake in the contact lens maker roughly a year ago. It began pushing Cooper to replace CEO Albert White and its board […]
❖Sep 26, 5:11 PMnewsvia finnhub
Is Cooper Companies (COO) Undervalued After Opening Its New Vision Centre?
Cooper Companies (COO) just opened The Vision Centre in Southampton, a global hub that brings together research, clinical work, pilot manufacturing, and advanced technology to help move new contact lens products toward market more quickly. The backdrop for this new hub is a share price that has retreated sharply over 2026. Cooper Companies has a 30 day share price return of down 23.8% and a year to date share price return of down 31.7%, while the 1 year total shareholder return is down 18%...
❖Sep 24, 9:31 AMnewsvia finnhub
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
The Cooper Companies opens a global innovation hub in England and unveils six contact lens programs to support sustainable long-term growth.
❖Sep 24, 5:51 AMnewsvia finnhub
CooperCompanies (COO) Keeps CooperSurgical and Expands Buybacks. What Did the Strategic Review Reveal?
With marginal growth across key metrics during the third quarter, The Cooper Companies Inc. (NASDAQ:COO) also finalized its strategic review process, which was initially announced in December last year. In Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision, we highlighted the company’s 1% year-over-year topline growth during the recently reported quarter, which […]
❖Sep 23, 4:15 PMnewsvia finnhub
CooperCompanies Unveils Accelerated CooperVision Innovation Strategy at The Vision Centre Opening
The Vision Centre Brings Industry Leading Innovation to Accelerate Breakthroughs in Eye CareSAN RAMON, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today reinforced its commitment to accelerate growth at CooperVision with the opening of its new global innovation hub, The Vision Centre, and the announcement of six major product advancements that have been accelerated to launch over the next several years: The build-out of the world's first & only complete family of 1-d
❖Sep 23, 10:00 AMnewsvia finnhub
CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements
CooperVision today unveiled the grand opening of The Vision Centre, the company's new global innovation hub in Southampton, England, and announced six major product advancements that have been accelerated to launch over the next several years. The announcements were made as CooperVision brings together research and development, clinical expertise, pilot manufacturing, advanced technologies, and commercial capabilities to accelerate the development and commercialization of breakthrough solutions
❖Sep 21, 7:47 AMnewsvia finnhub
Activist investor urges Cooper Companies to replace CEO, sell some assets
Citing “chronic underperformance,” Jana Partners is calling for new leadership and for the company to evaluate the sale of its fertility and medical device assets.
❖Sep 21, 7:18 AMnewsvia finnhub
3 Out-of-Favor Stocks with Open Questions
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
❖Sep 20, 8:02 PMnewsvia finnhub
A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?
For almost nine months, The Cooper Companies, Inc. (NASDAQ:COO) has been trying to sell its CooperSurgical unit. But on September 9, 2026, the company ended the strategic review it had launched in December 2025 and decided to keep the business. The reason is that the bids received were not in shareholders’ interest and reflected a […]
❖Sep 19, 7:00 AMnewsvia finnhub
Costco, BlackBerry To Headline Earnings In A Muted Week
Preview next weekâs market movers: Fed, yields, PMI, jobless claims, durable goods, earnings (Costco, BB), dividends & IPOs. Read here for more.
❖Sep 18, 3:05 PMnewsvia finnhub
Top S&P500 movers in Friday's session
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.
❖Sep 18, 12:35 PMnewsvia finnhub
Discover which S&P500 stocks are making waves on Friday.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
❖Sep 18, 10:37 AMnewsvia finnhub
How Is Cooper Companies' Stock Performance Compared to Other Medical Instruments & Supplies Stocks?
As Cooper Companies has lagged behind its industry peers over the past year, Wall Street analysts maintain a cautious outlook on its prospects.
❖Sep 18, 9:04 AMnewsvia finnhub
1 Value Stock with Impressive Fundamentals and 2 We Turn Down
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
❖Sep 18, 7:54 AMnewsvia finnhub
‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search
Activist firm Jana Partners calls for leadership overhaul and asset sales at Cooper Companies (COO) amid governance concerns.
❖Sep 18, 7:37 AMnewsvia finnhub
Activist Calls for Cooper Cos. to Seek New CEO. What It Means for the Barron’s Stock Pick.
Cooper Cos. stock rises as activist investor Jana Partners calls for the company to search for a new CEO and sell a key business segment.
❖Sep 18, 7:14 AMnewsvia finnhub
The Bull Case For Cooper Companies (COO) Could Change Following CooperSurgical Retention And Capital Plan Shift
In September 2026, The Cooper Companies completed a broad strategic review, ultimately deciding to retain CooperSurgical after assessing potential sale offers, while also outlining revised capital allocation plans and operational initiatives for CooperVision and CooperSurgical. The Board cited temporary factors such as a new competitor in non-hormonal IUDs and the impact of recent fertility litigation settlements as reasons for a perceived valuation gap that made selling CooperSurgical less...
▣Sep 3, 8:00 PMjournaltime_stop
Agent 20 — SIR Price/Volume closed long 26 @ $70.64 (+$85.54)
Time stop: held 91 ≥ 90 days
▣Jul 30, 8:00 PMjournalexpired_settlement
options_momentum closed long 100 @ $2.32 (-$140.03)
SETTLED 2026-09-17 (mig 257): contract expired 2026-07-31 while the agent was disabled; settled at intrinsic 2.3200 from underlying close 72.32 (Massive, unadjusted). Was carried at stale 7/2 mark 5.8863.
▢Jun 24, 8:00 PMjournal
options_momentum opened long 100 @ $3.72
▣Jun 16, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.52 (-$72.78)
Stop: premium $2.52 ≤ trailing floor $2.77 (peak $3.69 × 0.75)
▣Jun 10, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.87 (-$3.49)
Stop: premium $2.87 ≤ trailing floor $2.93 (peak $3.91 × 0.75)
▢Jun 10, 8:00 PMjournal
options_momentum opened long 100 @ $3.25
▢Jun 8, 8:00 PMjournal
Agent 7 — Day Trader opened long 44 @ $68.09
▣Jun 8, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 44 @ $68.64 (+$24.42)
EOD forced close — day trader never carries overnight
▢Jun 7, 8:00 PMjournal
options_momentum opened long 100 @ $2.91
▢Jun 4, 8:00 PMjournal
Agent 20 — SIR Price/Volume opened long 26 @ $67.35

← Back to dashboard